Answers are grounded in this paper and cite their sources.
Shows improved nanomedicine delivery in solid tumors, suggesting a new approach for treatment efficacy.
Intratumoral delivery remains a major limitation for nanomedicines in solid tumors, particularly in drug-resistant tumors containing efflux-dominant cellular subpopulations. Using P-glycoprotein (Pgp)-associated resistance as a clinically relevant model of heterogeneous transport barriers, we developed a spatiotemporally controlled strategy to improve nanomedicine delivery through selective depletion of efflux-dominant cells. Pgp-targeted photoimmunotherapy (PIT) selectively eliminated Pgp-overexpressing cells and increased intracellular retention of nanoparticle albumin-bound paclitaxel (nab-paclitaxel), accompanied by ATP redistribution associated with reduced efflux activity. In heterogeneous tumor models, PIT enhanced tumor-level nanoparticle accumulation and improved the antitumor efficacy of nab-paclitaxel compared with monotherapy. In vivo, the combination produced durable tumor suppression without increased systemic toxicity. These findings support the potential of spatiotemporally controlled depletion of efflux-dominant cells to relieve intratumoral transport constraints and enhance nanomedicine delivery.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: